TP53 and ovarian cancer: Interrogation of The Cancer Genome Atlas (TCGA) revealed that patients bearing TP53 mutated ovarian cancer with low expression of glycolytic markers and IL-6 receptor together with an efficient autophagy machinery survive longer and are more responsive to the platinum therapy.